Exagamglogene autotemcel
Brand names: Casgevy · Active ingredient: Exagamglogene Autotemcel
In short: CASGEVY is indicated for the treatment of patients aged 2 years and older with: sickle cell disease (SCD) with recurrent vaso-occlusive crises transfusion-dependent β-thalassemia (TDT)
What is Exagamglogene autotemcel used for?
CASGEVY is indicated for the treatment of patients aged 2 years and older with:
sickle cell disease (SCD) with recurrent vaso-occlusive crises
transfusion-dependent β-thalassemia (TDT)
Exagamglogene autotemcel dosage
For autologous use only. For one-time, single dose intravenous use only.
The minimum recommended dose of CASGEVY is 3 × 106 CD34+ cells/kg.
CASGEVY is provided as a single dose for infusion containing a suspension of CD34+ cells in one or more vials. See the Lot Information Sheet provided with the product shipment for additional information pertaining to the number of vials required to achieve the patient-specific dose. Administer all vials.
Confirm that autologous hematopoietic stem cell (HSC) transplantation is appropriate for the patient before mobilization, apheresis and myeloablative conditioning are initiated.
It is recommended that patients with SCD weigh at least 12 kg prior to start of mobilization since patients below this weight may experience difficulty in achieving the minimum target cell dose.
Screen patients for HIV-1, HIV-2, HBV, HCV, and any other infectious agents in accordance with local guidelines before collection of cells for manufacturing. CASGEVY should not be used in patients with active HIV-1, HIV-2, HBV or HCV.
Discontinue disease modifying therapies (e.g., hydroxyurea, crizanlizumab) 8 weeks before the planned start of mobilization and conditioning .
Preparation for Mobilization and Apheresis
Sickle Cell Disease: Prior to planned start of mobilization, it is recommended to transfuse red blood cells (RBCs) (simple or exchange) as needed, for a minimum of 8 weeks and continue until initiation of myeloablation or reinitiate transfusion for a minimum of 8 weeks prior to start of myeloablation with a goal to maintain hemoglobin S (HbS) levels < 30% of total hemoglobin (Hb) while keeping total Hb concentration ≤ 11 g/dL.
Transfusion-dependent β thalassemia: Prior to planned start of mobilization, it is recommended to transfuse RBCs as needed, with a goal to maintain hemoglobin (Hb) ≥ 11 g/dL and continue until start of myeloablation or reinitiate transfusion for at least 60 days prior to start of myeloablation.
Mobilization and Apheresis
HSC mobilization followed by apheresis to isolate the CD34+ cells is required to manufacture CASGEVY. Refer to the prescribing information for the mobilization agent(s) used, prior to treatment. See Clinical Studies (14) for description of the mobilization agents used in the clinical trials. Alternative mobilization regimens may be considered if clinically indicated.
Sickle Cell Disease: Administer plerixafor 0.24 mg/kg/day via subcutaneous injection 2 to 3 hours prior to planned apheresis for a maximum of 3 days. Do not use Granulocyte Colony-Stimulating Factor (G-CSF) for mobilization in patients with SCD.
Transfusion-dependent β thalassemia: Administer G-CSF for 5 to 6 days, starting 4 days prior to plerixafor administration. …
How to take Exagamglogene autotemcel — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information).
Prior to treatment, advise patients or caregivers of the following:
Risks of mobilization and conditioning agents - Advise patients of the risks associated with mobilization and myeloablative conditioning agents and to read the FDA-approved patient labeling (Patient Information) for these agents.
Potential need for additional cell collection - Ensure patients understand that if the minimum dose of CASGEVY is not met after initial product manufacturing, additional cycles of mobilization and apheresis will be needed to collect additional cells for product manufacture .
Concomitant medications - Advise patients of the need to avoid the following medications:
Disease modifying therapies (e.g., hydroxyurea, crizanlizumab) should be discontinued 8 weeks before the planned start of mobilization and conditioning .
Iron chelation should be stopped at least 7 days prior to myeloablative conditioning. …
Warnings & precautions
Do not take this medicine if: None.
There is potential risk of neutrophil engraftment failure after treatment with CASGEVY. In the clinical trials, all treated patients achieved neutrophil engraftment and no patients received rescue CD34+ cells.
Monitor absolute neutrophil counts (ANC) and manage infections according to standard guidelines and medical judgement. In the event of neutrophil engraftment failure, patients should be infused with rescue CD34+ cells . Granulocyte Colony-Stimulating Factor (G-CSF) is not recommended for 21 days after CASGEVY infusion.
Delayed platelet engraftment has been observed with CASGEVY treatment. There is an increased risk of bleeding until platelet engraftment is achieved .
Monitor patients for bleeding according to standard guidelines and medical judgement. Conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved. Perform blood cell count determination and other appropriate testing whenever clinical symptoms suggestive of bleeding arise.
Hypersensitivity reactions, including anaphylaxis, can occur due to dimethyl sulfoxide (DMSO) or dextran 40 in the cryopreservation solution. Monitor patients for hypersensitivity reactions during and after infusion.
The risk of unintended, off-target editing in an individual's CD34+ cells cannot be ruled out due to genetic variants. The clinical significance of potential off-target editing is unknown.
Exagamglogene autotemcel side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most common Grade 3 or 4 non-laboratory adverse reactions (occurring in ≥ 25%) were mucositis and febrile neutropenia in patients with SCD and patients with TDT, and decreased appetite in patients with SCD.
All (100%) of the patients with TDT and SCD experienced Grade 3 or 4 neutropenia and thrombocytopenia. Other common Grade 3 or 4 laboratory abnormalities (≥ 50%) include leukopenia, anemia and lymphopenia.
Sickle Cell Disease
The safety of CASGEVY in patients with SCD was evaluated in two open-label, single-arm trials (Trial 1 and Trial 4) and a long-term follow-up trial that included patients with SCD and TDT (Trial 3). Trial 1 included 44 patients 12 years and older and Trial 4 included 11 patients 5 years to less than 12 years of age. Patients were treated with CASGEVY after undergoing myeloablative conditioning with busulfan.
Trial 1 (patients 12 years and older)
The median (min, max) duration of follow-up for 44 patients with SCD after being administered CASGEVY was 19.3 (0.8, 48.1) months.
Serious adverse reactions after myeloablative conditioning and CASGEVY infusion were observed in 45% of patients with SCD. …
Drug interactions
No formal drug interaction studies have been performed. CASGEVY is not expected to interact with the hepatic cytochrome P-450 family of enzymes or drug transporters.
Granulocyte Colony-Stimulating Factor (G-CSF) must not be used for CD34+ HSC mobilization of patients with SCD .
Discontinue the use of hydroxyurea at least 8 weeks prior to start of each mobilization cycle and conditioning. There is no experience of the use of hydroxyurea after CASGEVY infusion.
Discontinue the use of crizanlizumab at least 8 weeks prior to start of mobilization and conditioning, as its interaction potential with mobilization and myeloablative conditioning agents is not known.
Discontinue the use of iron chelators at least 7 days prior to initiation of myeloablative conditioning, due to potential interaction with the conditioning agent. Some iron chelators are myelosuppressive. If iron chelation is required, avoid the use of non-myelosuppressive iron chelators for at least 3 months and use of myelosuppressive iron chelators for at least 6 months after CASGEVY infusion. Phlebotomy can be used instead of iron chelation, when appropriate.
The safety of immunization with live viral vaccines during or following CASGEVY treatment has not been studied.
About this medicine
CASGEVY (exagamglogene autotemcel) is a cellular gene therapy consisting of autologous CD34+ HSCs edited by CRISPR/Cas9-technology at the erythroid specific enhancer region of the BCL11A gene to reduce BCL11A expression in erythroid lineage cells, leading to increased fetal hemoglobin (HbF) protein production.
CASGEVY is prepared from the patient's own HSCs, which are obtained via apheresis procedure(s). The autologous cells are enriched for CD34+ cells, and then genome edited ex vivo by introducing the CRISPR/Cas9 ribonucleoprotein (RNP) complex by electroporation. The guide RNA included in the RNP complex enables CRISPR/Cas9 to make a precise DNA double-strand break at a critical transcription factor binding site (GATA1) in the erythroid specific enhancer region of the BCL11A gene. As a result of the editing, GATA1 binding is disrupted and BCL11A expression is reduced. This reduction in BCL11A expression conversely results in an increase in gamma-globin expression and downstream fetal hemoglobin formation. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7c3e12ad-e2fe-4d3f-a630-ea7364d9e846. Read the full official label on DailyMed.